Menu
← Oncology Approval Tracker
FDA DECISION ·
Talzenna + Xtandi
talazoparib + enzalutamide · Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For metastatic castration-resistant prostate cancer with a homologous recombination repair gene mutation.
LAMPGEN ANALYSIS
Why it matters
The combination extended PARP inhibition into an HRR-defined prostate cancer regimen.
What research teams should watch
Verify the individual HRR alteration and schedule blood-count monitoring for the combination.
PRIMARY RECORDS